User login

We offer our registered users tailored information, free online courses and exclusive content.

You have an old EXCEMED account ...

Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?

... or you lost your password?

6th EMEA forum on cardiovascular risks

6th EMEA forum on cardiovascular risks
  • Cardiometabolic
  • Hypertension
Regional workshop by Excemed
Saturday, Nov 18 2017
Lisbon, Portugal

Accreditation

EBAC

Language

English

Registration status
Closed

Target audiences

Cardiologists and internists involved in preventing and managing patients with cardiovascular risk factors or who are experiencing cardiovascular diseases.

Files

Introduction

Access learning resources by clicking the Outcomes tab or scroll down to the Scientific Programme.

Overview

This  live  educational  conference  will  look  at  available  evidence on  specific  and  relevant  topics  related  to  cardiovascular  disease. Discussion  will  focus  on  increased  sympathetic  activity  in  the pathogenesis of hypertension-related heightened cardiovascular risk and the need to consider high heart rate as a target for treatment. The role of combination treatment in hypertension and recent novelties in the availability of fixed dose formulations will also be addressed. Treating the main hypertension - related clinical conditions, including acute coronary syndrome and heart failure, will also be discussed. Another  major  topic  of  interest  will  be  to  the  optimal  timeline for  treating  diabetic  patients  with  beta-blockers  and  if  there  are differences among different molecules of this class.

Time will also be dedicated to interactive clinical case discussions which  will  translate  results  from  controlled  clinical  trials  and guidelines into applications for daily clinical practice.

Learning objectives

By  attending  this  live  educational  programme,  participants  will  be able to:
• Highlight sympathetic nervous system over activity as a pathogenetic mechanism in hypertensive-related cardiovascular risk and discuss if  this  parameter  can  be  considered  a  target  in  antihypertensive treatment
• Discuss  the  role  of  fixed  dose  combinations  in  the  treatment  of hypertension and address the therapeutic relevance of the new fixed dose combination beta-blocker/calcium antagonist
• Identify  the  best  practice  according  to  guidelines  for  treating hypertensive patients with coronary artery disease
• Manage the complex transition from hypertension to heart failure and  discuss  the  possible  beneficial  effect  of  pharmacological
treatment
• Select the best beta-blocker compound when treating patients with diabetes

Accreditation details

An application will be made to the European Board for Accreditation in Cardiology (EBAC) for CME accreditation of the “6th EMEA forum on cardiovascular  risks”, to be held on 18 November 2017 in Lisbon, Portugal.

Scientific programme

Saturday, 18 November 2017

08.20                   Opening and introduction
                            G. Mancia (Italy)

Session I

08.30     L1          Sympathetic nervous system and cardiovascular risk

                            G. Mancia (Italy)

08.50     L2          Should increased heart rate be considered a target in cardiovascular treatment?

                            H. A.J. Struijker-Boudier (The Netherlands)

09.10    L3           New possibilities for the fixed-dose combination treatment in hypertension

                            S. Taddei (Italy)

09.30                   Panel discussion

09.50                   Coffee break

 

Session II

10.10    L4           Best practice in the management of stable chronic angina

                            B. Tomlinson (Hong Kong)    

10.30    L5           From hypertension to heart failure: prevention strategies

                            E. Erdmann (Germany)

10.50    L6           Use of betablockers in diabetes

                            G. Grassi (Italy)

11.10                   Panel discussion

Session III

11.30 Working groups

This session includes two different parallel workshops, each lasting 1 hour. Participants will be divided into groups and will attend both workshops in rotation. By the end of the session each participant will have attended both workshops.

WG1                  The role of beta-blockers in hypertensive patients

                           Presenter: H. A.J. Struijker-Boudier (The Netherlands)

                           Discussant: B. Tomlinson (Hong Kong)

WG2                   How to optimize treatment in patients with heart failure

                           Presenter: E. Erdmann (Germany)

                           Discussant: S. Taddei (Italy)

13.30                  Take home messages from the working groups and wrap up

13.50                  Closing remarks

                           G. Mancia (Italy)

14.00                  End of the workshop

                           Closing lunch

 

CME provider

EXCEMED - Excellence in Medical Education

Chair(s)

Giuseppe Mancia

Department of Clinical Medicine
University of Milano-Bicocca
Milan, Italy
Speakers

Stefano Taddei

Department of Clinical and Experimental Medicine
Hypertension Unit
University of Pisa
Pisa, Italy

Brian Tomlinson

Specialist in Internal Medicine & Clinical Pharmacology
Department of Medicine and Therapeutics
Adjunct Professor
The Chinese University of Hong Kong
Hong Kong, China

Giuseppe Mancia

Department of Clinical Medicine
University of Milano-Bicocca
Milan, Italy

Erland Erdmann

Department of Cardiology
University of Köln
Köln, Germany

Guido Grassi

Department of internal medicine
University of Milano-Bicocca
Milan, Italy

Registration/Accommodation

The registration fee is 150€ and includes:
• Access to scientific sessions
• Educational materials
• Certificate of attendance
• Coffee break and luncheons
Dinners are not included.